Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney DiseaseBusiness Wire • 04/24/24
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & ExpoBusiness Wire • 04/07/24
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical DataBusiness Wire • 03/25/24
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic DystrophyBusiness Wire • 03/08/24
Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 MillionBusiness Wire • 01/05/24
Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common StockBusiness Wire • 01/03/24
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney DiseaseBusiness Wire • 12/21/23
Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 12/20/23
Arrowhead Pharma offers 'an attractive mix' of early and late-stage programs, analysts sayProactive Investors • 12/04/23